Early growth response protein 3 (EGR3)

Early growth response protein 3 (EGR3), also known as PILOT and zinc finger protein pilot, is an immediate-early transcription factor belonging to the EGR family of C2H2-type zinc-finger proteins. It is rapidly induced by mitogenic, inflammatory, or stress signals and functions to regulate gene expression in response to environmental and cellular stimuli. EGR3 plays crucial regulatory roles in controlling biological rhythms, muscle and neuronal development, immune homeostasis, and endothelial cell migration. In pathology, EGR3 mediates profibrotic responses in fibroblasts, contributing to tissue remodeling and scleroderma. In cancer, notably prostate and breast cancer, EGR3 is overexpressed and upregulates key inflammatory mediators (e.g., IL6, IL8), promoting tumor progression, angiogenesis, and immune crosstalk. Though no drugs directly target EGR3, its expression is a candidate biomarker for disease prognosis and may be an attractive target for future therapeutic modulation.

Other names

Early growth response 3EGR-3PILOTZinc finger protein pilotEarly growth response protein 3

Hypothetical drugs targeting EGR3 could act via transcription inhibition, preventing EGR3 binding to promoter regions of inflammatory and fibrotic genes, thereby downregulating gene expression (IL6, IL8, etc.). They could also modulate immune pathways by altering cytokine and interleukin production downstream of EGR3 activity, and antagonize tissue remodeling and fibrosis by reducing fibrotic gene expression driven by EGR3.